J. Pris-connaissance-du-formulaire-et-je-comprends-le, les avantages, les risques et les inconvénients du projet de recherche Je suis satisfait(e) des explications, précisions et réponses que le chercheur m'a fournies, le cas échéant, quant à ma participation à ce projet. ______________________________________Date : _______________________________________ Signature du participant

J. Le, les avantages, les risques et les inconvénients du projet de recherche au participant. J'ai répondu au meilleur de ma connaissance aux questions posées et j'ai vérifié la compréhension du participant, Date : ____________________________________ Signature du chercheur REFERENCES BIBLIOGRAPHIQUES

D. Regier, M. Farmer, and D. Rac, Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study, JAMA: The Journal of the American Medical Association, vol.264, issue.19, pp.2511-2519, 1990.
DOI : 10.1001/jama.264.19.2511

L. Dixon, Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes, Schizophrenia Research, vol.35, pp.93-100, 1999.
DOI : 10.1016/S0920-9964(98)00161-3

E. Duaux and A. Dervaux, Toxicomanie et schizophrénie Séminaire de psychiatrie biologique : hôpital Sainte, Anne, vol.30, pp.93-112, 2000.

. Washington, DC: House of Representatives, Committee on Ways and Means, 1937.

J. Joy, S. Watson, and J. Benson, Marijuana and Medicine: Assessing the Science Base, 1999.

A. Mack and J. Joy, Marijuana as medicine? The Science Beyond the Controversy

P. Mura, M. Perrin, M. Chabrillat, and H. Chaudron, Dumestre-Toulet V. L'augmentation des teneurs en THC dans les produits à base de cannabis en France : mythe ou réalité ?, Annal Toxicol Anal, vol.13, issue.13, pp.64-71, 2001.

M. Paris and N. Tran, The existence of "Nederwiet", a new fact in the history of cannabis, Ann Pharm Fr, vol.56, issue.146, pp.264-271, 1998.

Y. Barguil, Etude de trois plantes psychotropes consommées en Nouvelle-Calédonie : kava, cannabis et datura ? Aspects médicaux et médico-légaux [thèse], p.158, 2011.

M. Huestis, A. Sampson, B. Holicky, J. Henningfield, and E. Cone, Characterization of the absorption phase of marijuana smoking, Clinical Pharmacology and Therapeutics, vol.52, issue.1, pp.31-41, 1992.
DOI : 10.1038/clpt.1992.100

M. Huestis, G. Nahas, K. Sutin, D. Harvey, and S. Agurell, Pharmacokinetics of THC in Inhaled and Oral Preparations, Marijuana and medicine. Totowa. New Jersey, pp.105-121, 1999.
DOI : 10.1007/978-1-59259-710-9_11

J. Lindgren, A. Ohlsson, S. Agureil, L. Hollister, and H. Gillespie, Clinical effects and plasma levels of ?9-Tetrahydrocannabinol (?9-THC) in heavy and light users of cannabis, Psychopharmacology, vol.31, issue.3, pp.208-220, 1981.
DOI : 10.1007/BF00427095

M. Huestis, Human Cannabinoid Pharmacokinetics, Chemistry & Biodiversity, vol.169, issue.23, pp.1770-804, 2007.
DOI : 10.1002/cbdv.200790152

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689518

M. Wall, B. Sadler, D. Brine, H. Taylor, and M. Perez-reyes, Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women, Clinical Pharmacology and Therapeutics, vol.34, issue.3, pp.352-63, 1983.
DOI : 10.1038/clpt.1983.179

L. Hollister, H. Gillespie, A. Ohlsson, J. Lindgren, A. Wahlen et al., -Tetrahydrocannabinol Reflect the Degree of Intoxication?, The Journal of Clinical Pharmacology, vol.11, issue.S1, pp.171-177, 1981.
DOI : 10.1002/j.1552-4604.1981.tb02593.x

URL : https://hal.archives-ouvertes.fr/hal-00780688

G. Nahas, C. Leger, B. Tocque, and H. Hoellinger, The Kinetics of Cannabinoid Distribution and Storage With Special Reference to the Brain and Testis, The Journal of Clinical Pharmacology, vol.21, issue.S1, pp.8-9208, 1981.
DOI : 10.1002/j.1552-4604.1981.tb02597.x

C. Hunt and R. Jones, Tolerance and disposition of tetrahydrocannabionol in man, J Pharmacol Exp Ther, vol.215, issue.24, pp.35-44, 1980.

G. Sticht, H. Käferstein, and G. , Toxicokinetik und toxicodynamik, Cannabis im Strassenverkehr. Gustav Fischer, pp.1-11, 1998.

M. Huestis, J. Henningfield, and E. Cone, Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana, Journal of Analytical Toxicology, vol.16, issue.5, pp.276-82, 1992.
DOI : 10.1093/jat/16.5.276

S. Astley and R. Little, Maternal marijuana use during lactation and infant development at one year, Neurotoxicology and Teratology, vol.12, issue.2, pp.161-169, 1990.
DOI : 10.1016/0892-0362(90)90129-Z

M. Wall, B. Sadler, D. Brine, H. Taylor, and M. Perez-reyes, Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women, Clinical Pharmacology and Therapeutics, vol.34, issue.3, pp.352-63, 1983.
DOI : 10.1038/clpt.1983.179

R. Brenneisen, A. Egli, M. Elsohly, V. Henn, and Y. Spiess, The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients, Int J Clin Pharmacol Ther, vol.34, issue.3110, pp.446-52, 1996.

J. Goullé, E. Saussereau, and C. Lacroix, Pharmacocin??tique du delta-9-t??trahydrocannabinol (THC), Annales Pharmaceutiques Fran??aises, vol.66, issue.4, pp.232-244, 2008.
DOI : 10.1016/j.pharma.2008.07.006

R. Schwartz, G. Hayden, and M. Riddile, Laboratory detection of marijuana use. Experience with a photometric immunoassay to measure urinary cannabinoids, Journal of Ethnopharmacology, vol.17, issue.3, pp.1093-1099, 1985.
DOI : 10.1016/0378-8741(86)90131-5

G. Ellis, . Jr, M. Mann, B. Judson, N. Schramm et al., Excretion patterns of cannabinoid metabolites after last use in a group of chronic users, Clinical Pharmacology and Therapeutics, vol.38, issue.5, pp.572-580, 1985.
DOI : 10.1038/clpt.1985.226

J. Costentin, Neurobiologie du cannabis, La lettre du psychiatre, vol.8, issue.2, 2012.

L. Venance, R. Maldonado, and O. Manzoni, Le syst??me endocannabino??de central, m??decine/sciences, vol.20, issue.1, pp.45-53, 2004.
DOI : 10.1051/medsci/200420145

S. Potvin, E. Stip, and J. Roy, Schizophrenia and Cannabinoids, Drogues, sant?? et soci??t??, vol.2, issue.2, 2004.
DOI : 10.7202/008536ar

A. Caballero and K. Tseng, Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia, Frontiers in Pharmacology, vol.3, issue.38, p.101, 2012.
DOI : 10.3389/fphar.2012.00101

B. Gaborit and F. Andreelli, Le système endocannabinoïde : de la physiologie aux potentialités thérapeutiques, Sang Thrombose Vaisseaux, vol.20, pp.129-165, 2008.

M. Fouchet, Signes cliniques de l'imprégnation au cannabis. 5. In : Palazzo J, Roure L. Le cannabis : du plaisir au risque. Tout comprendre pour mieux prendre en charge. Clamecy : Med-line Editions, p.69, 2005.

C. Ashton, Pharmacology and effects of cannabis: a brief review, The British Journal of Psychiatry, vol.178, issue.2, pp.137-147, 2002.
DOI : 10.1192/bjp.178.2.101

R. Gurley, R. Aranow, and M. Katz, Medicinal Marijuana: A Comprehensive Review, Journal of Psychoactive Drugs, vol.274, issue.2, pp.137-184, 1998.
DOI : 10.1056/NEJM198903233201203

J. Joy, J. Stanley, W. Jr, and J. Benson, Consequences of marijuana use and abuse. In: Marijuana and medicine: Assessing the science base, 1999.

V. Fontaa, Le médecin et le toxicomane : guide pratique, p.123

L. Karila, J. Vignau, C. Alter, and M. Reynaud, Altération cognitive liée à la consommation aigue et chronique de cannabis, La revue du praticien, vol.55, issue.451, pp.23-26, 2005.

J. Macleod, R. Oakes, and A. Copello, Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies, The Lancet, vol.363, issue.9421, pp.1579-88, 2004.
DOI : 10.1016/S0140-6736(04)16200-4

L. Iversen, The science of marijuana, 2000.
DOI : 10.1093/acprof:oso/9780195328240.001.0001

X. Laqueille, Troubles Psychiatriques liés, induits ou associés au cannabis, La revue du praticien, vol.55, issue.1, pp.30-34, 2005.
DOI : 10.1016/j.pharma.2008.06.001

P. Beaconsfield, J. Ginsburg, and R. Rainsbury, Marihuana Smoking, New England Journal of Medicine, vol.287, issue.5, pp.209-212, 1972.
DOI : 10.1056/NEJM197208032870501

R. Kumar, W. Chambers, and R. Pertwee, Pharmacological actions and therapeutic uses of cannabis and cannabinoids, Anesthesia, vol.56, issue.5011, pp.1058-68, 2001.

J. Delile, Usages de cannabis : repérage et évaluation des facteurs de gravité, La revue du praticien, vol.55, pp.51-63, 2005.

P. Kintz, V. Cirimele, and B. Ludes, Detection of Cannabis in Oral Fluid (Saliva) and Forehead Wipes (Sweat) from Impaired Drivers, Journal of Analytical Toxicology, vol.24, issue.7, pp.557-61, 2000.
DOI : 10.1093/jat/24.7.557

P. Kintz, V. Cirimele, G. Pepin, P. Marquet, M. Deveaux et al., Identification et dosage des cannabinoïdes dans le sang total, Toxicorama, vol.8, issue.54, pp.29-33, 1996.

M. Moulsma, L. Humbert, A. Citterio-quentin, and J. Wiart, Traité de toxicologie médicojudiciaire . Méthodes analytiques, pp.139-194

M. Huestis, J. Henningfield, and E. Cone, Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of Delta9- tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCCOOH), J Anal Toxicol, issue.565, pp.16283-290, 1992.

M. Uhl, Determination of cannabinoids in human hair. Analytical and practical aspects of drug testing in, Hair, pp.127-141, 2006.

J. Goullé and P. Kintz, Le cheveu: un efficace marqueur biologique d'exposition aux xénobiotiques, Ann Biol Clin, vol.55, issue.585, pp.435-477, 1997.

V. Cirimele, (International Diagnostic Systems Corp.) pour le d??pistage des x??nobiotiques dans les cheveux??: bilan de 2 ans d'activit??, Annales de Toxicologie Analytique, vol.21, issue.1, pp.9-12, 2009.
DOI : 10.1051/ata/2009028

G. Kauert and J. Röhrich, Concentrations of Delta 9-tetrahydrocannabinol

M. Huestis, R. Gustafson, E. Moolchan, A. Barnes, J. Bourland et al., Cannabinoid concentrations in hair from documented cannabis users, Forensic Science International, vol.169, issue.2-3, pp.2-3129, 2007.
DOI : 10.1016/j.forsciint.2006.08.005

S. Legleye, F. Beck, S. Spilka, X. Briffault, A. Gautier et al., Exploitation des données du Baromètre santé 2005 relatives aux pratiques d'usage de substances psychoactives en population adulte, Tendances, vol.48, 2006.

S. Legleye, F. Beck, S. Spilka, L. Nezet, and O. , Genre et caractéristiques sociales des consommateurs de drogues à l'adolescence, 2000.

S. Legleye, F. Beck, S. Spilka, and C. Lafitteau, Les drogues à 17 Ans. Résultats de l'enquête Escapad, Tendances, vol.66, 2008.

S. Spilka, L. Nezet, O. Tovar, and M. , Les drogues à 17 Ans : Premiers résultats de l'enquête Escapad, Tendances, vol.79, issue.68, 2011.

S. Spilka, L. Nezet, O. Beck, F. Ehlinger, V. et al., Alcool et Cannabis durant les années collège, Tendances, vol.80, issue.69, 2012.

C. Currie, C. Zanotti, A. Morgan, D. Currie, D. Looze et al., Social Determinants of Health and Well-being Among Young People, Health Behaviour in School aged Children (HBSC), 2009.

S. Spilka and . Résultats-du-volet-drogues, En France, de l'enquête Health Behaviour in School Aged Children (HBSC) 2010. Alcool, Tabac et Cannabis durant les 'Années Collège, Tendances, vol.80, 2012.

F. Beck, S. Legleye, and S. Spilka, Les évolutions de la consommation de cannabis sur les 15

. In, Consommation de cannabis : niveaux, évolution, géographie. OFDT, 2005.

S. Legleye, F. Beck, and S. Spilka, Niveaux d'usage et profils des usagers en France en, 2005.

F. Beck, S. Legleye, and P. Peretti-watel, Penser les drogues : Perceptions des produits et des politiques publiques. Enquête sur les représentations opinions et perceptions sur les produits psychotropes (EROPP), p.232, 2002.

B. Goodfellow, F. Calandreau, and R. J. , Psychiatric Epidemiology in New Caledonia, International Journal of Mental Health, vol.2, issue.4, pp.68-81, 2010.
DOI : 10.2753/IMH0020-7411390104

J. Macleod, D. Smith, G. Hickman, and M. , Does cannabis use cause schizophrenia?, The Lancet, vol.367, issue.9516, p.1055, 2006.
DOI : 10.1016/S0140-6736(06)68468-7

F. Liraud and H. Verdoux, Caractéristiques cliniques et pronostiques associées à une comorbidité addictive chez des patients hospitalisés en psychiatrie, Encéphale, vol.26, issue.3, pp.16-23, 2000.

H. Verdoux, Agitation et délire aigus, La revue du praticien, pp.61-427, 2011.

F. Leweke, A. Giuffrida, U. Wurster, H. Emrich, and D. Piomelli, Elevated endogenous cannabinoids in schizophrenia, NeuroReport, vol.10, issue.8, pp.1665-1674, 1999.
DOI : 10.1097/00001756-199906030-00008

B. Dean, S. Sundram, R. Bradbury, E. Scarr, and D. Copolov, Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use, Neuroscience, vol.103, issue.1, pp.9-15, 2001.
DOI : 10.1016/S0306-4522(00)00552-2

R. Alonso, B. Voutsinos, M. Fournier, C. Labie, R. Steinberg et al., Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function, Neuroscience, vol.91, issue.2, pp.607-627, 1999.
DOI : 10.1016/S0306-4522(98)00675-7

L. Dixon, A. Breier, and J. Lieberman, Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes, Schizophrenia Research, vol.35, pp.93-100, 1999.
DOI : 10.1016/S0920-9964(98)00161-3

A. Dervaux, J. Olie, X. Laqueille, F. Bayle, L. Borgne et al., Conduites addictives chez 100 schizophrènes, Encéphale, vol.25, issue.98, p.183, 1999.

J. Raynaud and L. Amétépé, Schizophrénie et comorbidité: addiction et violence, La revue du praticien, vol.52, issue.11, pp.1191-1194, 2002.

T. Chaltiel, T. Balkan, H. Lida-pulik, and M. Botbol, Dépendance et Cannabis: Une étude clinique auprès d'adolescents hospitalisés en milieu psychiatrique, Psychiatrique, vol.79, issue.100, pp.215-235, 2003.

S. Zammit, P. Allebeck, S. Andreasson, I. Lundberg, and G. Lewis, Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study, BMJ, vol.325, issue.7374, p.1199, 2002.
DOI : 10.1136/bmj.325.7374.1199

L. Arsenault, M. Cannon, R. Poulton, R. Murray, A. Caspi et al., Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study, BMJ, vol.325, issue.7374, pp.1212-1215, 2002.
DOI : 10.1136/bmj.325.7374.1212

K. Kristensen and K. Cadenhead, Cannabis abuse and risk for psychosis in a prodromal sample, Psychiatry Research, vol.151, issue.1-2, pp.151-155, 2007.
DOI : 10.1016/j.psychres.2006.10.001

M. Corcos, O. Phan, S. Nezelof, and P. Jeammet, Psychopathologie de l'adolescent fumeur de cannabis, La revue du praticien, vol.55, issue.1041, pp.35-40, 2005.

M. Reynaud, Cannabis, L'approche doit être scientifique, La Revue du Praticien, vol.55, pp.14-20, 2005.

M. Grall-bronnec, T. Balkan, and M. Botbol, Etudiants, usage de cannabis et troubles psychiatriques, Alcoologie et Addictologie, vol.27, issue.106, pp.21-29, 2005.

M. Meier, A. Caspi, A. Ambler, H. Harrington, and R. Houts, Persistent cannabis users show neuropsychological decline from childhood to midlife, Proceedings of the National Academy of Sciences, vol.109, issue.40, pp.2657-64, 2012.
DOI : 10.1073/pnas.1206820109

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479587

J. Van-os, M. Bak, M. Hanssen, R. Bijl, R. De-graaf et al., Cannabis Use and Psychosis: A Longitudinal Population-based Study, American Journal of Epidemiology, vol.156, issue.4, pp.319-327, 2002.
DOI : 10.1093/aje/kwf043

M. Hambrecht and H. Häfner, Cannabis, Vulnerability, and the Onset of Schizophrenia: An Epidemiological Perspective, Australian & New Zealand Journal of Psychiatry, vol.3, issue.33, pp.468-75, 2000.
DOI : 10.1080/j.1440-1614.2000.00736.x

Y. Murat, E. Bora, D. Lubman, N. Solowij, . Brewerwj et al., The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample, Schizophr Bull, vol.38, issue.2, pp.316-346, 2012.

C. Schubart, I. Sommer, V. Gastel, W. Goetgebuer, R. Kahn et al., Cannabis with high cannabidiol content is associated with fewer psychotic experiences, Schizophrenia Research, vol.130, issue.1-3
DOI : 10.1016/j.schres.2011.04.017

URL : http://doi.org/10.1016/j.schres.2011.04.017

C. Morgan and H. Curran, Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis, The British Journal of Psychiatry, vol.192, issue.4, pp.306-307, 2008.
DOI : 10.1192/bjp.bp.107.046649

A. Martín-moreno, D. Reigada, B. Ramírez, R. Mechoulam, N. Innamorato et al., Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease, Molecular Pharmacology, vol.79, issue.6, pp.964-73, 2011.
DOI : 10.1124/mol.111.071290

F. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C. Gerth et al., Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, Translational Psychiatry, vol.152, issue.3, p.94, 2012.
DOI : 10.1038/tp.2012.15

P. Laure and C. Binsinger, Consommation de produits ?? aux fins de performance ?? par les m??decins g??n??ralistes, Th??rapie, vol.58, issue.5, pp.445-50, 2003.
DOI : 10.2515/therapie:2003072

J. Parker and M. Gay, Problem drug users known to bristol general practitionners, Journal of the royal college of general practitioners, vol.37, pp.260-263, 1987.

F. Beck, R. Guignard, I. Obradovic, A. Gautier, and L. Karila, Développement du repérage des pratiques addictives en médecine générale en France. Revue d'épidémiologie et de santé publique, pp.285-294, 2011.

S. Legleye, L. Kraus, D. Piontek, O. Phan, and C. Jouanne, Validation of the Cannabis Abuse Screening Test in a Sample of Cannabis Inpatients, European Addiction Research, vol.18, issue.4, pp.193-200, 2012.
DOI : 10.1159/000336553

J. Delile, Usages de cannabis : repérage et évaluation des facteurs de gravité, La revue du praticien, vol.55, p.62, 2005.

L. Karila, S. Legleye, F. Beck, E. Corruble, B. Falissard et al., Validation of a questionnaireto screen for harmful use of alcohol and cannabis in the general population: CRAFFT-ADOSPA, pp.582-590, 2007.

G. Berger, R. Fraser, S. Carbone, and P. Mcgorry, Emerging psychosis in young people, Australian Family Physician, vol.35, issue.5, pp.315-336, 2006.

M. Sim, E. Khong, and G. Hulse, Cannabis and psychosis, Australian Family Physician, vol.33, issue.4, pp.229-261, 2004.

C. Bernard, P. Melihan-cheinin, N. Postel-vinay, M. Jeanfrançois, and F. Lert, Agir contre la hausse du cannabis, La revue du praticien, vol.55, pp.5-6, 2005.

J. Prochaska, C. Diclemente, H. Prochaska, J. Diclemente, C. Norcross et al., The Transtheoretical Approach, American Psychologist, issue.125126, 1984.
DOI : 10.1093/med:psych/9780195165791.003.0007

. Guilbert, A. Gautier, F. Baudier, and A. Trugeon, Baromètre santé 2000 : les comportements des 12-25 ans synthèse des résultats nationaux et régionaux, INPES, vol.3, issue.127, p.216, 2004.

C. Gerada, Cannabis and the general practitioner 'going to pot, British Journal of General Practice, vol.53, pp.598-599, 2003.

I. Obradovic, Caractéristiques du public reçu dans les consultations jeunes consommateurs pour un problème d'addiction, BEH, vol.30, pp.332-336, 2005.
DOI : 10.3917/lcd.056.0088

C. Jurado, M. Menéndez, M. Repetto, P. Kintz, V. Cirimele et al., Hair Testing for Cannabis in Spain and France: Is There a Difference in Consumption?, Journal of Analytical Toxicology, vol.20, issue.2, pp.111-116, 1996.
DOI : 10.1093/jat/20.2.111

M. Huestis, R. Gustafson, and E. Moolchan, Cannabinoid concentrations in hair from documented cannabis users, Forensic Science International, vol.169, issue.2-3, pp.2-3129, 2007.
DOI : 10.1016/j.forsciint.2006.08.005

D. Forti, M. Morgan, C. Dazzan, and P. , High-potency cannabis and the risk of psychosis, The British Journal of Psychiatry, vol.195, issue.6, pp.488-91, 2009.
DOI : 10.1192/bjp.bp.109.064220

S. Bhattacharyya, P. Morrison, and P. Fusar-poli, Opposite Effects of ??-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology, Neuropsychopharmacology, vol.20, issue.3, pp.764-74, 2010.
DOI : 10.1038/npp.2009.184

T. Winton-brown, P. Allen, and S. Bhattacharyya, Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study, Neuropsychopharmacology, vol.154, issue.7, pp.1340-1348, 2011.
DOI : 10.1590/S0100-879X2006000400001

URL : https://hal.archives-ouvertes.fr/hal-00624169

P. Fusar-poli, J. Crippa, and S. Bhattacharyya, Distinct Effects of ??9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing, Archives of General Psychiatry, vol.66, issue.1, pp.95-105, 2009.
DOI : 10.1001/archgenpsychiatry.2008.519

R. Martin-santos, J. Crippa, and A. Batalla, Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers, Current Pharmaceutical Design, vol.18, issue.32, pp.4966-79, 2012.
DOI : 10.2174/138161212802884780

M. Mann and G. Pons, Pharmacog??n??tique et traitements anti??pileptiques, EMC - Neurologie, vol.2, issue.3, pp.308-329, 2005.
DOI : 10.1016/j.emcn.2005.01.006